Endogenex is a clinical stage company focused on improving outcomes and quality of life for patients living with Type 2 Diabetes (T2D). Endogenex has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa for improvement in glycemic control in patients with T2D.
Location: United States, Minnesota, Plymouth
Employees: 11-50
Total raised: $100M
Founded date: 2017
Investors 3
| Date | Name | Website |
| 26.10.2023 | Lumira Ven... | lumiravent... |
| - | Intuitive ... | ventures.i... |
| 22.06.2021 | Longitude ... | longitudec... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.06.2024 | Series C | $88M | - |
| 19.04.2021 | - | $12M | - |
Mentions in press and media 7
| Date | Title | Description |
| 15.10.2024 | Endogenex™ Announces First Patient Enrolled in the ReCET Clinical Study | Achieving a Significant Clinical Milestone in Assessing the ReCET™ System as a Groundbreaking Treatment for Type 2 Diabetes MINNEAPOLIS, Oct. 15, 2024 /PRNewswire/ -- Endogenex, Inc., a clinical-stage medical device company focused on impro... |
| 06.07.2024 | Endogenex: $88 Million Raised To Improve Outcomes In Individuals With Type 2 Diabetes | Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes, announced it closed an oversubscribed Series C financing totaling $88 million. The new funding round will be used to com... |
| 25.06.2024 | Endogenex™ Announces $88 Million Series C Financing to Complete Pivotal Trial of the ReCET™ System in Patients with Type 2 Diabetes | Oversubscribed financing led by strategic investor, with participation from new and existing investors MINNEAPOLIS, June 25, 2024 /PRNewswire/ -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individu... |
| 25.06.2024 | Endogenex Raises $88M in Series C Financing | Endogenex, a Minneapolis, MN-based clinical-stage medical device company, raised $88M in Series C funding. Backers included Hatteras Venture Partners, Lumira Ventures, Orlando Health Ventures, Intuitive Ventures, Longitude Capital, Mayo Cli... |
| 01.02.2024 | Endogenex Receives IDE Approval to Initiate Pivotal Clinical Study | A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of the ReCET™ System in Adult Patients with Type 2 Diabetes Endogenex, Inc., a clinical stage medical device company dedicated to improving outcomes in patients ... |
| 30.01.2024 | Endogenex Receives IDE Approval to Initiate Pivotal Clinical Study | A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of the ReCET™ System in Adult Patients with Type 2 Diabetes MINNEAPOLIS, Jan. 31, 2024 /PRNewswire/ -- Endogenex, Inc., a clinical stage medical device company d... |
| - | Endogenex | “Novel treatment solutions to address Type 2 Diabetes for patients, providers and healthcare systems around the world. In partnership with Mayo Clinic.” |